Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase EARLY_PHASE1 1Phase 2 1Phase 1/2 1

Status

Unknown 11Recruiting 9Completed 7Withdrawn 2Active not recruiting 2Terminated 1Not yet recruiting 1Enrolling by invitation 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Breast Neoplasms 24Carcinoma, Non-Small-Cell Lung 20Neoplasms 19Colorectal Neoplasms 19Recurrence 17Pancreatic Neoplasms 17Multiple Myeloma 15Advanced Solid Tumors 13Prostatic Neoplasms 12Advanced Solid Tumor 12Stomach Neoplasms 10Ovarian Neoplasms 10Leukemia, Myeloid, Acute 10Carcinoma, Hepatocellular 10Triple Negative Breast Neoplasms 8Neoplasm Metastasis 7Melanoma 7Squamous Cell Carcinoma of Head and Neck 6Small Cell Lung Carcinoma 6Lymphoma, Large B-Cell, Diffuse 6Head and Neck Neoplasms 6Glioblastoma 6Urinary Bladder Neoplasms 5Solid Tumors 5Solid Tumor 5Lymphoma, B-Cell 5Lung Neoplasms 5Liver Neoplasms 5Glioma 5Endometrial Neoplasms 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Not yet recruiting × Leukemia, B-Cell × Clear all
NCT06979076 2025-09-29

A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLL

MingSight Pharmaceuticals, Inc

Phase 1/2 Not yet recruiting
12 enrolled
LymphoidOther hematologic neoplasm

Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡